Please use agentic internet research to find articles or media abou the 14 Day Rule.
###
Yes—there is meaningful public coverage, including op-eds specifically attacking the inpatient 14-day rule. But your impression is right: the discussion remains concentrated in oncology and physician media. I did not locate a verified Politico, Washington Post, or The Hill article specifically examining the inpatient rule’s harm to genomic testing. That leaves a plausible opening for a broader policy story.
The strongest findings follow, prioritized for your communications effort.
1. KevinMD: an entire physician op-ed on precisely your issue
“Medicare’s 14-day rule is hurting cancer patients” — Sean Jordan, MD, July 5, 2024.
This is the closest match to the opinion piece you envision. Jordan, a thoracic surgeon, describes the difficulty of ordering molecular testing after inpatient lung cancer surgery. He explicitly distinguishes 14 days after discharge from 14 days after surgery, explains the outpatient exception, and argues that the remaining inpatient policy delays results and subsequent systemic treatment.
He also describes the substantial work his institution undertook to establish compliant pathways. An excellent precedent—and Jordan is a potential clinician source for a reporter. kevinmd.com
2. OncoDaily: another piece devoted entirely to the inpatient rule
“Daniel Flora: The 14-Day Rule – When Bureaucracy Delays Cancer Care” — October 25, 2025.
This republishes a Substack post by Daniel Flora, medical oncologist and medical director of oncology research at St. Elizabeth Healthcare. He describes the postdischarge waiting period, followed by laboratory turnaround, potentially stretching the delay to a month or more. He calls for CMS and professional societies to reform the policy.
This is public physician advocacy rather than independently reported journalism, but it is exceptionally direct and accessible. OncoDaily
3. The ASCO Post: recent commentary from a prominent oncologist
“Access Denied: Insurance Barriers to Biomarker Testing in Lung Cancer” — Charu Aggarwal, MD, MPH, FASCO, July 25, 2026.
Aggarwal explicitly identifies the inpatient 14-day rule as an administrative barrier that delays treatment. The article places it within the larger mismatch between precision oncology and insurance policy, including the growing importance of testing in earlier-stage disease.
Especially useful given ASCO’s participation in your coalition, although an individual author’s commentary should not be presented as an official ASCO position. The ASCO Post
4. AJMC: reporting published just this week
“Overcoming Barriers to Precision Care and Patient Access” — Brooke McCormick, September 28, 2026.
Reporting on a Seattle oncology meeting, McCormick identifies the rule as a persistent barrier. Siddhartha Devarakonda of Providence Swedish Cancer Institute calls it “a huge disservice to our patients.” The article discusses clinicians’ use of rapid assays and outpatient ctDNA testing to address urgent diagnostic needs.
This provides a recent reporter byline, named clinical sources, and descriptions of practical consequences—all useful for developing a national story. AJMC
5. MUSC Hollings: a public-facing research story explaining the clinical stakes
“From biopsy to biomarker results: Hollings researchers uncover surprising results in turnaround time” — June 19, 2026.
The story features Adam Fox and Gerard Silvestri, discusses lengthy biopsy-to-result intervals, and expressly identifies the inpatient 14-day rule as a potential contributor. It explains why patients diagnosed during hospitalization still need biomarkers to guide subsequent outpatient care.
It also explains why starting treatment before results can have consequences beyond simply switching drugs later. However, the reported turnaround-time findings do not establish how much delay the rule itself caused. MUSC Hollings Cancer Center
Additional public coverage worth keeping in the packet
| Outlet and item | Relevance |
|---|---|
| Targeted Oncology, February 9, 2024: “Worth The Wait? Genomic Testing Delays Initiation of Advanced NSCLC Therapy”, Jonah Feldman | Reports oncologists discussing the 14-day postdischarge barrier alongside laboratory turnaround and pressure to start treatment. Immunotherapy, Biomarkers, and Cancer Pathways |
| OncLive, 2022: “Genomic Testing Challenges Persist” | Tracey Evans discusses the rule’s particular difficulty for patients hospitalized with urgent NSCLC symptoms. An earlier example of clinician-focused reporting. OncLive |
| AJMC, July 6, 2026: Video discussion on biomarker-testing barriers in extrapulmonary neuroendocrine carcinoma | Identifies the inpatient rule as especially problematic for fast-growing tumors. Useful evidence that the concern extends beyond lung cancer. AJMC |
| LUNGevity, October 9, 2025: “Removing Obstacles to Drive Timely Precision Medicine for Patients” | Publicly reports that, among surveyed respondents who applied the rule, 78% reported treatment delays and 40% reported treatment decisions sometimes preceding results. These are respondent reports, not percentages of patients harmed. LUNGevity Foundation |
The historical coverage is also useful—and includes you.
Turna Ray’s November 3, 2017 GenomeWeb article, “CMS 14-Day Rule Revisions Ease Precision Medicine Access for Patients, Stakeholders Say”, is available as a public PDF through LUNGevity. It discusses delayed access, quotes LUNGevity, and cites your analysis repeatedly. It concerns the outpatient reform, making it useful background for a story about the inpatient problem that remained. lungevity.org
There is also a November 14, 2024 CAP public advocacy update describing support for a resolution urging changes so that complex testing on inpatient specimens can be paid separately, consistent with outpatient rules. That helps demonstrate that the concern reaches beyond laboratories and individual oncologists. CAP
Two considerations for the media pitch
First, some existing pieces say Medicare prohibits testing or requires physicians to wait. Your coalition can explain this more accurately: the rule creates a payment and billing barrier that can cause testing to be delayed; it does not prohibit clinically indicated testing during the window. CMS’s own explanation anchors the rule in specimen collection and order timing, with a qualifying outpatient exception. The ASCO Post article also appears to miscite the regulation; CMS identifies 42 CFR 414.510, not 410.508. CMS
Second, another public narrative already exists: enforcement against laboratories accused of manipulating the rule. DOJ’s 2022 Caris and 2023 Genomic Health announcements expressly discuss delayed cancer tests, but frame the problem as improper billing and circumvention. A reporter may encounter these quickly, so reform advocacy should distinguish the policy’s adverse incentives from defending violations of existing requirements. United States Department of Justice
My assessment is that you have ample published precedent to substantiate a pitch, while the issue still appears underexplored in general-interest policy journalism. The most useful starting packet would be Jordan’s op-ed, Aggarwal’s commentary, the September 28 AJMC reporting, and the MUSC story—paired with a documented patient timeline and the coalition’s concrete reform request.
One search limitation: The Hill and Politico restricted direct access. LUNGevity lists a December 2018 Hill opinion piece about lung-cancer treatment access, but I could not verify its contents and therefore have not counted it as coverage of the 14-day rule. LUNGevity Foundation
